A Novel Target for Treatment of Rare Genetic Diseases Caused by Nonsense Mutations

Summary of the technology

Duchenne Muscular Dystrophy (DMD) and Becker Dystrophy
Molecules tested on patient-derived cells: 5-AzaC, Ataluren, Amlexanox, +8 new drugs
Project ID : 6-2018-4579

Yissum - Research Development Company of the Hebrew University

Details of the Technology Offer


A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein, such as dystrophin in Duchenne muscular dystrophy. Nonsense mutations caused by premature stop codon, are treated using read-through therapies that are only partially efficient since they rely on the existence of mutant mRNA which is unstable.

Our Innovation

The proposed invention is anovel target for the treatment of genetic diseases caused by nonsense mutations, which increases the success of current read through therapies, and may serve as a stand-alone treatment in cases that premature stop codon is not involved but the mRNA is unstable for other reasons.


  • Novel target with several proposed small molecules to inhibit this target (repositioning of existing drugs).
  • since the compounds are small molecules, they are stable, dosage-regulated, and have increased penetration to all body tissues – advantage in Duchenne delivery to muscles, and CF delivery to the lungs.
  • In-vitro results using cells derived from Duchene and Becker patients show increased mRNA stability.

The Opportunity

  • Nonsense mutation are the cause of many genetic diseases, such as Duchenne/Becker, Cystic fibrosis and others. Despite rapid developments over the last years, there remains a large unmet need among patients who are not amenable to mutation-specific drugs.
  • Duchenne, Becker and CF are rare diseases and considered orphan diseases by the FDA with an accelerated regulatory path.
  • Existing read-through drugs have poor effectiveness. The technology suggests increased effectiveness and relief of Duchenne symptoms.
  • This technology is applicable for other genes and not limited to Dystrophin (Becker and Duchenne target) or CFTR (Cystic fibrosis).
  • The team has the capabilities to advance the technology up to pre-clinical studies.

Development Milestones

Preliminary results to support the core of the invention were obtained in patient-derived cells.

Next steps are in-vivo studies

Figure 1. A general scheme of nonsense mutation causing mRNA degradation and mRNA stabilization by targeted drugs.

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Rotem Karni
HUJI, School of Medicine - IMRIC
Biochemistry and Molecular Biology

Related Keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • small molecule

About Yissum - Research Development Company of the Hebrew University

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Yissum - Research Development Company of the Hebrew University

Never miss an update from Yissum - Research Development Company of the Hebrew University

Create your free account to connect with Yissum - Research Development Company of the Hebrew University and thousands of other innovative organizations and professionals worldwide

Yissum - Research Development Company of the Hebrew University

Send a request for information
to Yissum - Research Development Company of the Hebrew University

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support